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Qualitative and Quantitative Differences
in T Cell Receptor Binding
of Agonist and Antagonist Ligands
some cases, these cells were nonresponsive to antigen
and thus functionally negatively selected (Hogquist et
al., 1995; Girao et al., 1997). In contrast, ªtrueº positive
selection of antigen-responsive cells was obtained with
suboptimal agonist or antagonist ligands (Hogquist et
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TCR-TCR or TCR-coreceptor cross-linking is required
for activation by MHC-peptide complexes, but there areSummary
conflicting data on the specifics (Boniface et al., 1998;
Delon et al., 1998).The kinetics of interaction between TCR and MHC-
Several models have been produced to account forpeptide show a general relationship between affinity
the different signaling properties of optimal versus sub-and the biological response, but the reported kinetic
optimal ligands. Most data show a relationship betweendifferences between antigenic and antagonistic pep-
T cell activation and the dissociation rate and/or affinitytides are very small. Here, we show a remarkable dif-
of the TCR for its ligand (Sykulev et al., 1994a; Al-Ramadiference in the kinetics of TCR interactions with strong
et al., 1995; Alam et al., 1996; Lyons et al., 1996; Schodinagonist ligands at 378C compared to 258C. This differ-
et al., 1996), which can be described by kinetic modelsence is not seen with antagonist/positive selecting
of TCR interaction (Kersh and Allen, 1996; Madrenasligands. The interaction at 378C shows biphasic bind-
and Germain, 1996). These implicate the relative off-ing kinetics best described by a model of TCR dimer-
rates of the ligands as the principal determining fac-ization. The altered kinetics greatly increase the stabil-
tor in discriminating optimal from suboptimal ligandsity of complexes with agonist ligands, accounting for
(McKeithan, 1995; Rabinowitz et al., 1996). This is con-the large differences in biological response compared
sistent with the requirement for coreceptor involvementto other ligands. Thus, there may be an allosteric, as
in determining the outcome of receptor engagements,well as a kinetic, component to the discrimination be-
since short-lived TCR-ligand complexes would dissoci-tween agonists and antagonists.
ate before effectively recruiting the coreceptor, while
long-lived complexes would allow coreceptor engage-
Introduction ment (Hampl et al., 1997). However, some anomalous
results have been obtained that could be explained by
The phenomenon of T cell antagonism, where recogni- conformational changes in TCR being required for signal
tion of suboptimal ligands (i.e., antagonist or partial ago- transduction (reviewed by Janeway, 1995; Madrenas
nist ligands) leads to a partial activation of the cell or and Germain, 1996; Kersh and Allen, 1996). For example,
the inhibition of responses to coadministered agonist certain class I-peptide ligands that are clearly recog-
ligands, was the first intimation of the complexities of nized by CTL have very low-affinity binding to the TCR
signal transduction through the T cell receptor (TCR) (Al-Ramadi et al., 1995; Schodin et al., 1996). In another
(Kersh and Allen, 1996; Madrenas and Germain; 1996). case, an antagonist ligand has a lower affinity for cell
Such suboptimal ligands sustained positive selection of surface TCR than does a weak agonist (Sykulev et al.,
CD8 single-positive thymocytes, while optimal (agonist) 1998). Moreover, we previously showed that the biologi-
ligands induced negative selection (Hogquist et al., cal potency of optimal versus suboptimal ligands was
1994). Although low concentrations of optimal ligands not completely correlated with the off-rates of the li-
promoted development of CD8 single-positive cells in gands, suggesting that simple kinetic proofreading
mechanisms could not account for partial signaling
through the TCR (Alam et al., 1996).‖ To whom correspondence should be addressed (e-mail: p.travers@
rfhsm.ac.uk [P. J. T.], gascoigne@scripps.edu [N. R. J. G.]). We have investigated the interaction between TCR
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Figure 1. Temperature-Dependent Binding of
TCR OT-1 to Its Antigenic Ligand, OVA-Kb
The effect of temperature on TCR-MHC bind-
ing is shown on an amine-coupled OVA-Kb
surface maintained at (a) 68C, (b) 258C, and
(c) 378C. Soluble OT-1 TCR was injected at
concentrations of 20, 8, 4, and 2 mM in (a)
and 16, 8, 4, and 2 mM in (b) and (c). Binding
to the same OVA-Kb surface was measured at
258C, then at 378C, and finally at 68C. Binding
curves at 378C show slower, biphasic kinetics
during both association and dissociation
phases. In (d), the significant effect of temper-
ature on the binding kinetics is demonstrated
by overlaying sensorgrams that have reached
the same RU level at the end of the associa-
tion phase (180 s) at each temperature. At
378C, TCR binding to antigen-MHC occurs
with a much slower on- and off-rate. This
change in binding kinetics is evident only at
temperatures above 308C as shown in (e)
where binding of 10 mM sTCR was measured
at 298C, 328C, and 378C. The temperature de-
pendency of the kinetics is orientation-spe-
cific: (f) shows a titration of OVA-Kb at 2.5, 5,
10, and 15 mM flowing over a TCR immobi-
lized surface equilibrated at 378C. Binding at
258C of 15 mM OVA-Kb to the same surface
is shown (dotted line) for comparison. In this
orientation, no change in kinetics is observed
at 378C.
and agonist/negative selecting versus antagonist/posi- (Figure 1a), the TCR binds with a slightly slower on- and
off-rate compared to 258C (Figure 1b). However, at 378Ctive selecting ligands using surface plasmon resonance
(SPR). At physiological temperature, the TCR undergoes the TCR-MHC interaction was biphasic; the maximal
binding (Rmax: the apparent Rmax is read at the end ofa change in its kinetics of binding and dissociation with
agonist ligands compared to the interaction at lower TCR injection) at a fixed sTCR concentration increased,
and a temperature-dependent kinetic change was evi-temperature. This change in kinetics is not seen with
antagonist ligands and results in a large difference be- dent (Figure 1c). The association and dissociation
phases appear to be much slower at 378C than at 258C.tween the stability of TCR-agonist and TCR-antagonist
complexes. The kinetics of agonist binding at 378C are The change in kinetics can be seen most clearly when
the sTCR concentration is varied to yield the same Rmaxcompatible with a model where TCR undergoes dimer-
ization after an initial monomeric binding event. at the different temperatures (Figure 1d). Figure 1e
shows that the increase in Rmax occurred mainly above
328C, although a slight change in the kinetics was evi-Results
dent at this temperature. While the measurements of
TCR affinity made at 258C are not affected by whetherTemperature Dependence of Binding Kinetics
Direct measurements of TCR interactions with ligands it is the sTCR or the OVA-Kb complex that is immobilized
(Alam et al., 1996), the kinetic differences observed athave generally been performed in BIAcore biosensors
at 258C or with cells at room temperature or 48C, whereas 378C were not seen when sTCR, rather than OVA-Kb,
was immobilized to the sensor chip (Figure 1f).biological experiments are performed at 378C. The im-
portance of temperature as a variable was suggested A possible explanation for a failure to observe a
change in kinetics when the sTCR is immobilized mightby observations in one system, where TCR affinity for
two of five MHC-peptide complexes tested increased be increased heterogeneity in TCR orientation due to
the amine coupling (Fisher and Fivash, 1994; Karlsson,at 378C compared to 48C (Schlueter et al., 1996). We
therefore characterized the binding of a soluble (s)TCR 1994; Oddie et al., 1997). Problems with ligand heteroge-
neity in this system can be avoided by capturing TCRto its ligand at different temperatures. The TCR OT-1
(also called 42.12) recognizes as antigen (agonist) an proteins on an anti-Cb-immobilized surface (Alam et al.,
1996). These surfaces were unstable at 378C, due toovalbumin-derived peptide, OVA (SIINFEKL), bound to
H-2Kb, as well as a series of related peptides bound to a faster off-rate (Figure 2a). This largely obscured the
differences in binding rates of OVA-Kb to the capturedKb as agonist, antagonist, or null ligands (Hogquist et
al., 1994, 1995; Jameson et al., 1994). We immobilized TCR (Figure 2b), but it is clear that no significant change
in kinetics occurred between 258C and 378C. This sug-OVA-Kb complexes on a BIAcore sensor chip and mea-
sured binding at 68C, 258C, and 378C (Figure 1). At 68C gests that the orientation dependence of the change in
Agonist/Antagonist Discrimination by TCR
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Figure 2. Binding Kinetics of OT-1 TCR Uni-
formly Immobilized Using an Anti-Cb An-
tibody
(a) Anti-Cb was amine-coupled to a CM5 sen-
sor chip to a level of 8000 RU. Binding of the
TCR to the immobilized anti-Cb was mea-
sured at 258C (dashed line) and at 378C (solid
line). The binding to and, in particular, the
dissociation of the TCR from anti-Cb is faster
at 378C than 258C.
(b) The binding of OVA-Kb complexes to a
surface generated by binding the OT-1 TCR
to immobilized anti-Cb, as in (a), was mea-
sured at either 258C (dashed line) or 378C
(solid line). Arrows indicate the time point at
which the soluble proteins were injected.
The complex nature of TCR binding at 378C
is not due to trivial factors.
(c) Changes in flow rate have no effect on the
nature of binding kinetics. 9 mM TCR was
injected at 10, 20, and 50 ml/min over an OVA-
Kb surface at 378C; these are shown superim-
posed and reveal no significant differences
in binding kinetics.
(d) OVA-Kb proteins are not denatured or ag-
gregated by incubation at 378C. OT-1 binding
to the same surface equilibrated first at 258C
(curve 1), then at 378C (curve 2), and finally
at 258C again (curve 3) was measured. The
two 258C binding curves are similar, indicat-
ing that the changes observed in binding ki-
netics at 378C are reversible. The sTCR pro-
tein (15 mM) injected in the final 258C cycle was also preincubated at 378C and cooled down to 258C before being injected. Thus, there were
no irreversible changes in either the injected TCR or the immobilized Kb proteins upon incubation at 378C. In (c) and (d), OVA-Kb proteins were
immobilized by maleimide coupling chemistry.
(e) TCR proteins do not self-associate or aggregate on the sensor chip maintained at 378C. OT-1 TCR and OVA-Kb proteins were immobilized
by amine coupling. 12.5 mM of sTCR protein was injected over these surfaces in series at 378C. While binding is observed on the OVA-Kb
surface, no binding is observed on the TCR surface.
kinetics does not result from steric effects imposed by poorly to binding curves generated at 378C, which show
more complex interactions (see below). In BIAcore mea-direct immobilization of the TCR but that the sTCR needs
to be unconstrained in order to demonstrate this change surements of protein-protein binding, complex binding
interactions representing multiphasic association andin binding. These data also show that up to 800 RU of
sTCR do not result in aggregation or precipitation of the dissociation curves have often been reported. In some
cases, these have been found to be due to nonkineticreceptor onto the sensorchip matrix. We also investi-
gated the effect of uniform coupling of the MHC-peptide factors (Fisher and Fivash, 1994; Karlsson, 1994; Oddie
et al., 1997), including heterogeneity in ligand immobili-complexes, utilizing recombinant b2m proteins that had
a cysteine residue incorporated onto the surface. For zation and binding under mass transport limitation
(Karlsson, 1994; Schuck, 1996). We showed above thatOVA-Kb proteins incorporating these b2m molecules,
maleimide coupling chemistry (O'Shanessy et al., 1992) heterogeneity in ligand orientation was not responsible.
Under most binding conditions, mass transport limita-produced a uniform orientation of MHC proteins on the
sensor surface. These surfaces resulted in higher activ- tion is not likely to be a serious problem in measuring
TCR-MHC interactions, simply because of their slowity of Kb molecules (2-fold higher binding to anti-Kb anti-
bodies compared to an amine coupled surface; data not association rates (Schuck, 1996). We did not observe
any change in the initial phases of the binding kineticsshown). This chemistry was also good for preparing low-
density surfaces. The same effect of temperature on at higher flow rates (10±50 ml/min) (Figure 2c). Including
mass transport in the model fitting process for bindingbinding kinetics was observed using uniformly coupled
Kb-peptide complexes as with amine-coupled com- curves generated at 258C did not improve the fit (diffu-
sion constant, kt values generated from these fits wereplexes (data not shown).
,106). Thus, the binding kinetics observed at 378C are
not constrained by mass transport limitations nor areNonkinetic Factors Do Not Explain the Complex
TCR Binding Phases at 378C they due to any significant effect from heterogeneity in
ligand immobilization.The binding kinetics measured at 378C show a marked
difference from those measured at 258C and 68C. As To eliminate the possibility that the observed changes
in kinetics and Rmax were due to some irreversiblereported previously (Alam et al., 1996), TCR-MHC bind-
ing kinetics measured at 258C can be described by a change, i.e., aggregation or denaturation of the proteins
at the higher temperature, we made measurements atsimple Langmuir equation. This model, however, fits
Immunity
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Table 1. Kinetics of TCR OT-1 Binding to Agonists, Antagonists, and Null Ligands Measured at 258C and 378C
Ligand (peptide-Kb)
kon koff Kd t1/2
M21s21 s21 mM s
Binding at 258C
OVA SIINFEKL 3720 6 796b 0.022 6 4e-3b 5.9 31.5
A2 SAINFEKL 4800 6 814b 0.020 6 3e-3b 4.4 34.7
E1 EIINFEKL 3362 6 479b 0.065 6 7e-3 20.3 10.7
V-OVA RGYNYEKL 1942 6 78 0.035 6 7e-3 18.2 19.8
R4 SIIRFEKL 2672 6 152 0.110 6 2e-2b 40.1 6.3
polyser SSYSYSSL Ð .0.2 Ð (,3.5)
Binding at 378C
OVAa step 1 2040 6 748 0.0280 6 8e-3 13.0
step 2 570 6 119b 0.0013 6 5e-4b 1.9 533.2
A2a step 1 1769 6 326 0.0230 6 3e-3 14.4
step 2 531 6 141b 0.0010 6 2e-4b 1.7 693.1
E1 2200 6 300b 0.059 6 2.1e-2 26.8 11.7
V-OVA 2595 6 360 0.033 6 4e-3 12.7 21.0
R4 2615 6 91.9 0.070 6 2e-2b 26.9 9.9
polyser Ð .0.2 Ð (,3.5)
The rate constants were derived from the kinetic model that gave the best fit (a correlation coefficient .0.9 and a random residual plot). All
binding curves generated at 258C (for both agonist and antagonist ligands) were described by the simpler Langmuir equation (A 1 B 5 AB).
This model was also used for E1, V-OVA, R4, and polyser ligands at 378C.
a The dimerization model (Step 1, A 1 B 5 AB; Step 2, A 1 AB 5 AAB) was used to determine the rate constants for binding to agonist ligands
at 378C only (OVA and A2). Values for Kd were calculated as Kd 5 koff/kon. The reported rate constants are mean values (6SD) derived from at
least three different measurements. Global fitting of 378C curves for binding to OVA-Kb using the dimerization model gave slightly different
results: step 1, kon 5 2200M21s21, koff 5 0.023s21; step 2, kon 5 970M21s21, koff 5 0.0019s21.
b Significant difference between 258C and 378C rates (p , 0.05, t-test). On-rates: OVA, p , 0.001; A2, p , 0.001; E1, p 5 0.02; R4 and V-OVA
differences were nonsignificant. Off-rates: OVA, p , 0.001; A2, p , 0.001; R4, p 5 0.05; E1 and V-OVA differences were nonsignificant. On
and off-rates at 378C were significantly different between OVA or A2 and the other ligands. OVA and A2 were not significantly different from
each other. E1, V-OVA, and R4 did not differ significantly from each other in on-rate. In off-rate, V-OVA and R4 differed significantly (p 5
0.03), but the combinations E1/V-OVA and E1/R4 were not significantly different.
258C, 378C, and then 258C on the same OVA-Kb-surface. (Figure 3b) was rejected due to poor fit (R2 5 20.32),
particularly of the association phase. This model is de-There was no difference between the two 258C measure-
scribed as (A 1 B 5 AB; AB 5 AB*), where the dissocia-ments (Figure 2d). We also preheated the sTCR to 378C
tion constant of AB* in this case would be slower thanfor 30 min, cooled it to 258C, and tested its binding at
that of AB. The heterogeneous ligand model describing258C. The binding kinetics were similar to the other 258C
two independent binding and dissociation events (A 1measurements. Any changes in the TCR or in the MHC-
B1 5 AB1; A 1 B2 5 AB2) gave a better fit (Figure 3c;peptide complex are therefore fully reversible. Another
R2 5 0.90). However, this model does not explain thepossibility was that TCR undergoes homotypic binding
increased binding at 378C. Also, off-rate measurementsat 378C. Solution phase sTCR was tested for binding to
after differing contact times argue against this modelimmobilized sTCR or OVA-Kb at 378C (Figure 2e). No
(Figure 3f), where TCR was allowed to bind for varyingTCR-TCR binding was seen under these conditions,
lengths of time to OVA-Kb at 378C, and the maximaldemonstrating that the effect seen with TCR binding
binding normalized to 100 RU. Off-rates were measuredto OVA-Kb at 378C was not due simply to interactions
during the fast dissociation phase of the curves (25 s,between TCR molecules.
Figure 3g). As shown in Figure 3h, increasing contact
time results in correspondingly slower off-rates. This
Curve-Fitting of Binding Kinetics Is Consistent would not be the case for the heterogeneous ligand
with Dimerization of the TCR model, which describes two parallel events occurring
To account for the observed binding kinetics, we consid- simultaneously and where the off-rates themselves do
ered a number of models of binding. The 258C binding not vary with contact time. Rather, these data suggest
curves fit to the simple Langmuir equation (A 1 B 5 that the 378C curves reflect biphasic binding where the
AB), as previously reported (Alam et al., 1996). The calcu- second step is linked to an initial event. In agreement
lated kon and koff for the binding of sTCR to OVA-Kb at with this, the best fit was obtained with the dimerization
258C are 3720M21s21 and 0.022s21, respectively (Table model (Figure 3d; R2 5 0.998), which describes initial
1), which give a Kd of z6 mM, comparing well with the monomer binding to the ligand followed by a dimeriza-
data obtained earlier. The observed binding at 378C does tion event in which a second molecule of the species
not fit well to this model (Figure 3a, R2 5 0.83) and in solution binds to an existing ligand-receptor complex
displays more complex binding characteristics. Three (i.e., A 1 B 5 AB; A 1 AB 5 AAB). The form of the kinetic
additional models were therefore tested to analyze the curves at 378C is very similar to the curves seen in the
binding of MHC-peptide dimers to immobilized sTCR378C measurements. The conformational change model
Agonist/Antagonist Discrimination by TCR
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Figure 3. TCR Binding at 378C to Agonist Ligand Is Described by a Dimerization Model
(a±e) Curve-fitting plots of the binding of TCR to its antigenic ligand, OVA at 378C. Experimental (solid line) and fitted curves (dashed line) are
overlaid. The residuals from each of the fits are plotted. The 378C curves gave poor fit to both the simple (a) and conformational (b) models.
Although a better fit was obtained with the heterogeneous ligand model (c) (see text), binding at 378C was best described by the dimerization
model (d) (R2 5 0.998). (e) The two phases of the dimerization process in the 378C curve have been resolved into a fast and slow component.
The biphasic resolution of this curve was generated from a fit using the dimerization model (see Experimental Procedures) and BIAevaluation
3.0 software. In (f), TCR injection time was varied to determine whether the biphasic events occurring at 378C are linked. Binding curves
generated after injections of analyte for 360, 180, 90, and 30 s over an OVA-Kb surface at 378C were normalized to a response of 100 RU,
overlaid and aligned at the end of injection. In (g), the dissociation phases of the above plots are aligned to show the significant differences
in the off-rates, particularly during the initial fast phase (first 25 s of the dissociation phase). The off-rates were measured during this phase
of dissociation using the simple Langmuir model and are reported in (h). Comparison of the dissociation phases of the overlaid curves
demonstrates the dependence of off-rate on contact time, the off-rate being slower with increased contact time.
(Boniface et al., 1998). The difference between monomer of 0.0013s21 (z20-fold slower) and an on-rate (ka2) of
570M21s21 (3.6-fold slower), and may describe the di-and dimer binding in those experiments was similar to
the difference that we see between binding at 258C and merization process itself. Consistent with dimerization
of the analyte, binding at 378C gave Rmax values ap-378C, respectively. The 378C curves are also similar to
that seen when epidermal growth factor (EGF) receptors proaching 2-fold higher than those obtained at 258C (see
Figure 1). The calculated Kd derived from these ratedimerize on binding EGF, a case where ligand-induced
receptor dimerization is important in signaling (Zhou et constants are 13 and 1.9 mM for the initial and dimeriza-
tion steps, respectively. Since the slower off-rate is lim-al., 1993). Clearly, the dimerization model, unlike the
heterogeneous ligand model, can account for the in- iting, the half-life of the complex is estimated as 8.9 min,
a 17-fold increase over the half-life at 258C.creased level of TCR binding at 378C. The possibility
that the biphasic curves are due to binding of a mixture
of preformed TCR dimers as well as monomers is un- Stoichiometry of TCR Binding to OVA-Kb
Because the curve-fitting data suggest that the TCRlikely since we used gel filtration just before the experi-
ment in order to purify monomers and because sTCR undergoes dimerization at 378C, we determined the stoi-
chiometry of binding of sTCR to immobilized OVA-Kbdid not interact with immobilized TCR in Figure 2e.
Using the dimerization model to analyze the data and complexes at 378C in comparison to binding at 258C. At
258C, the binding kinetics approach steady-state withinresolve the components of the binding curve (Figure 3e),
the faster component of the interaction at 378C has a a short period of time, while at 378C higher binding is
observed that does not approach steady-state undersimilar off-rate (kd1 5 0.028s21) and a slightly slower on-
rate (ka1 5 2040M21s21) in comparison to the kinetics at our normal experimental conditions (e.g., Figures 1b and
1c; z1.5-fold-higher binding at 378C). Under appropriate258C (Table 1). This faster component (AB; Figure 3e)
describes the first event, the binding of a single sTCR immobilization conditions, steady-state binding can be
achieved at 378C with longer contact time. Figure 4amolecule to an MHC-peptide complex, and appears to
be similar to the binding observed at 258C. The second shows binding approaching steady-state, with a stoi-
chiometry of 1.80-fold over 258C binding. In Figure 4b,component (AAB) has a significantly slower off-rate (kd2)
Immunity
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Figure 4. Stoichiometry of Binding at 258C
and 378C
(a) Near equilibrium binding of sTCR to im-
mobilized OVA-Kb at 258C and 378C was
achieved by injecting sTCR for 80 and 180 s,
respectively. Approximately 1.80-fold more
sTCR protein was bound at 378C than at 258C.
In (b), the binding was allowed to reach satu-
ration. Steady-state binding conditions at
258C and 378C were reached after 80 and
280 s. The amount of sTCR bound at 378C
was 1.87-fold higher than at 258C. In both
experiments, net response was calculated
12 s after the start of the dissociation phase.
Stoichiometry of the interaction is shown in
the box. The experiment in (c) and (d) shows
overlays of TCR OT-1 binding curves that
reached the same level of binding at 258C to
OVA-Kb (agonist, 9 mM) and R4-Kb (antago-
nist, 15 mM) ligands (c). The same concentra-
tions of sTCR were then used to bind the
same immobilized Kb-peptide complexes at
378C (d). The agonist OVA-Kb ligand shows
altered kinetics and increased binding at
378C. The bulk response has been subtracted
from the curves shown in (c) and (d). The on- and off-rates calculated from this experiment are as follows: 258C; ka OVA-Kb 3270M21s21, R4-
Kb 2570M21s21; kd OVA-Kb 0.026s21, R4-Kb 0.085s21. At 378C; OVA-Kb ka1 1907M21s21, ka2 451M21s21, R4-Kb ka 2490M21s21; OVA-Kb kd1 0.034s21,
kd2 0.0014s21, R4-Kb kd 0.064s21.
steady-state binding is achieved after 80 s at 258C and LCMV glycoprotein peptide (Girao et al., 1997; Mariatha-
san et al., 1998), shows similar behavior with data thatafter 280 s at 378C, with a stoichiometry at 378C of 1.87-
fold over the level at 258C. These data, then, support fit the dimerization model (S. M. A., unpublished data).
The effect of temperature on sTCR binding is thus un-the notion that the sTCR undergoes dimerization after
binding ligand at 378C. likely to be an artifact of the particular receptor or restric-
tion element and appears to be a general phenomenon.
Binding of sTCR 149.13 to OVA-Kb
We tested the binding of another OVA-specific sTCR,
149.13, that differs from OT-1 in the CDR3a (Kelly et al., Binding of TCRs at 378C Differentiates between
Agonist/Negative Selecting and Antagonist/Positive1993). It binds to OVA-Kb with kinetics similar to OT-1
at both 258C and 378C (Figures 5a±5c). The 378C kinetics Selecting Peptide Ligand Complexes
To ask whether this effect of temperature on the kineticsof 149.13 binding also fit well to the dimerization model
(R2 5 0.95, data not shown). The half-life of 149.13:OVA- of binding was dependent on the nature of the MHC-
peptide complex, we investigated the interaction of theKb complexes (Figure 5d) is 21.7 s at 258C, compared
to 11.6 min at 378C, an increase of z32-fold. At the OT-1 sTCR with a number of agonist and antagonist
complexes that have been defined previously (Hogquisthigher concentrations of TCR, the Rmax at 378C is 1.83
that at 258C. A third receptor, specific for H-2Db plus an et al., 1994, 1995; Jameson et al., 1994; Alam et al.,
Figure 5. Binding Kinetics of TCR 149.13 Are
Similar to TCR OT-1
Binding of TCR 149.13 (at 3, 6, 10, and 20
mM) to OVA-Kb surface equilibrated at 258C
(a) and 378C (b). The binding curves at 378C
gave a good fit with the dimerization model
with kinetics similar to those for OT-1. (c)
Comparison of the 20 mM curves for 258C
versus 378C. The table in (d) shows the rate
constants measured for the 258C and 378C
binding using the simple and dimerization
model, respectively.
Agonist/Antagonist Discrimination by TCR
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Figure 6. Dimerization of TCR Molecules
upon Binding to Agonist but Not Antagonist
Ligands
The binding of OT-1 to various Kb-peptide
complexes was investigated at 258C (column
i) and at 378C (column ii). To facilitate compar-
ison between the results obtained at these
two temperatures, the binding curves at the
highest concentration of analyte are shown
superimposed (column iii). OT-1 binds to
strong agonist ligands OVA (a) and A2 (b) with
similar kinetics at 258C and undergoes dimer-
ization at 378C. The weak agonist/strong an-
tagonist E1 binds with slightly slower kinetics
at 378C but with no evidence for dimerization
(c). The strong antagonists R4 (d) and V-OVA
(e) show little or no difference in their kinetics
for binding to TCR at 258C and 378C. (f) shows
nonspecific binding to the null peptide poly-
ser. Data for OVA and A2 were generated on
two separate flow cells on the same sensor
chip. The binding data for E1 and those for
R4 and V-OVA are from three different experi-
ments. The highest concentrations of sTCR
injected were 10 mM for OVA and A2, 15 mM
for E1, and 20 mM for R4, V-OVA, and polyser
immobilized surfaces.
1996). The variant A2 (SAINFEKL) acts as a strong ago- 6c±6e iii). The null ligand polyser also showed no
change. Curve fitting to the simplest (A 1 B 5 AB) modelnist for OT-1 T cells, and in fetal thymus organ culture
(FTOC) it causes negative selection, requiring 5- to 10- afforded the best explanation of the kinetics of binding
of these ligands at both 258C (Figures 6c±6e i) and 378Cfold-more peptide than OVA for the same level of activ-
ity (Hogquist et al., 1995). The peptide E1 (EIINFEKL) is (Figures 6c±e ii), with R2 values from 0.9 to 0.97. The
dimerization model gave a poor fit to these data (R2 5a very weak agonist and strong antagonist, whereas
V-OVA (RGYNYEKL) and R4 (SIIRFEKL) are strict antag- 0.5±0.85). The measured rate constants between 258C
and 378C were not significantly different for these li-onists. All three peptides are positive selectors in FTOC.
Polyser (SSYSYSSL) is a null peptide (Hogquist et al., gands, with the exception of the kon for Kb-E1 and the koff
of Kb-R4, which were slower at the higher temperature.1994; Jameson et al., 1994).
The interaction of A2-Kb complexes with the OT-1 Thus, at 378C, the sTCR undergoes a major transforma-
tion in its binding kinetics when recognizing strong ago-sTCR shows the same phenomenon as the OVA-Kb li-
gand. At 378C (Figures 6a and 6b ii), both ligands showed nist ligands but not when recognizing antagonist li-
gands. This can be explained by a model of receptorbinding kinetics that fit the dimerization model. At 258C,
the kon for A2-Kb (Figure 6b i) was somewhat faster dimerization. The slow association curve for Kb-E1 at
378C suggests that this process may also be involved(4800M21s21 versus 3720M21s21) and the koff similar
(0.02s21) to those for OVA-Kb (Figure 6a i), resulting in in the very weak agonist activity of this ligand (see be-
low). The discrimination between strong agonist andan overall higher affinity of 4.4 mM for the A2-Kb ligand
(Table 1). The difference in kinetics between 258C and antagonist ligands is a strong argument against the pos-
sibility that aggregation of the sTCR at the higher tem-378C is clear (Figures 6a and 6b iii). On the other hand,
the antagonist/positive selecting complexes, E1-Kb, perature could account for the observed data; any het-
erogeneity in the sTCR preparation should be evidentV-OVA-Kb, and R4-Kb, showed little temperature-depen-
dent change in the kinetics of sTCR interaction (Figures whatever the ligand. Similar discrimination between ag-
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onist and antagonist ligands is seen in the Db-LCMV change to favor binding to other TCR molecules or core-
ceptors (Janeway, 1995; Kersh and Allen, 1996; Ma-system (S. M. A., unpublished data). Thus, in two inde-
pendent receptor systems, suboptimal ligands differ drenas and Germain, 1996). Other, architectural, models
involve a precise alignment of molecules after bindingfrom optimal ligands in their ability to induce dimeriza-
tion of the receptors. to agonist ligands that is not attained with other ligands,
for example, a precise alignment of TCR, MHC, andThe different behavior of agonist versus antagonist
ligand complexes allows us also to eliminate a potential coreceptor required for T cell activation or the higher
order structures found on the T cell surface at the pointsource of artifact in our observations. It is unlikely that
the effect that we see is due to nonspecific aggregation of contact with the APC (Madrenas and Germain, 1996).
Here, TCR and coreceptors are located in a small areaof the TCR onto a high local concentration of MHC de-
posited onto the chip, since this is unlikely to yield either at the contact region, surrounded by a ring of adhesion
molecules. These ordered clusters do not form in thethe observed linear relationship with the TCR concentra-
tion or the z2-fold ratio between the Rmax at the two presence of antagonist ligands (Monks et al., 1998). The
high concentration of receptors in the region of celltemperatures. However, we can eliminate this possible
artifact as an explanation, by comparing the binding of contact is likely to have a major effect on avidity, be-
cause it favors rebinding of ligand to receptors thatthe TCR to an agonist complex and to an antagonist
complex, at concentrations that, at 258C, yield the same are present in the cluster, resulting in slower apparent
dissociation (Posner et al., 1992).level of binding to the MHC-peptide surface. Since a
higher concentration of the TCR is necessary to achieve The data presented here suggest that TCR discrimina-
tion between agonist and suboptimal ligands includesbinding to the antagonist surface equivalent to that to
the agonist surface, any nonspecific aggregation should both a kinetic and an allosteric component, with TCR
dimerizing after binding to an agonist ligand. In thebe more pronounced. Yet, when we compare the binding
at similar concentrations at 378C (Figures 4c and 4d), growth factor ligand-receptor systems (e.g., EGF), the
ligand bridges two receptor molecules (Zhou et al.,only the TCR binding to the agonist surface shows the
increased binding and the altered kinetics. This point is 1993). This is not a viable model for TCR binding, and
our working hypothesis is that binding of a TCR moleculealso made in Figure 2a, where a large quantity (z800
RU) of TCR is bound to anti-Cb without precipitating to ligand induces a change allowing binding of a second
TCR to the first. Although we have not directly demon-either at 378C or at 258C. Clearly, then, nonspecific ef-
fects do not play a role in the phenomenon we have strated dimerization of TCR, the data suggest that a
single TCR molecule binds to the MHC-peptide complexobserved.
at a similar rate at both 258C and 378C. A (conforma-
tional) change then occurs at 378C, but not at 258C, after
Discussion which a second TCR molecule binds to the first. The
slower association rate for the weak agonist/strong an-
We have demonstrated a striking difference in the kinet- tagonist Kb-E1 at 378C, and for the agonist OVA-Kb at
ics of interaction between strong agonist ligands and the 328C, may indicate that for these complexes, the con-
TCR at physiological compared to lower temperatures. formational change occurs part way. On a cell surface,
This difference is not seen with weak agonist or antago- the longer half-life of agonist versus antagonist ligands
nist ligands. The kinetics at 378C are compatible with a may allow sufficient time for recruitment of coreceptor
model in which a single TCR molecule binds to the MHC- to the recognition complex (Hampl et al., 1997). Once
peptide complex, after which a second TCR molecule the coreceptor is associated with the recognition com-
binds to the first. This is likely to represent the first stage plex, the half-life of the complex is further increased
of TCR-ligand multimerization that occurs on the cell (Luescher et al., 1995; Garcia et al., 1996b) and specific
surface on recognition of antigen (Monks et al., 1998) interactions between different TCR and coreceptor (and
and in vitro at high concentration of TCR and agonist other) molecules lead to the formation of higher-order
ligand (Reich et al., 1997). structures (Madrenas and Germain, 1996; Reich et al.,
Kinetic models for TCR interactions rely on the off- 1997). These manifest as patches of TCR and coreceptor
rate of the TCR:MHC-peptide complex as the most cru- at the interface of the T cell and APC with agonists but
cial part of the system for discrimination of the signal not antagonists (Monks et al., 1998). Thus, although we
(McKeithan, 1995; Kersh and Allen, 1996; Madrenas and measure TCR dimerization in the BIAcore, higher order
Germain, 1996; Rabinowitz et al., 1996). For the majority multimerization of TCR, probably also with other mole-
of ligands tested to date, these models fit quite well, cules, would be the rule on a cell surface. (The nature
(Alam et al., 1996; Lyons et al., 1996). However, in our of the BIAcore experiment, with one molecule tied down,
previous experiments, a positive-selecting, antagonist precludes multimerization). This can explain the differ-
peptide (V-OVA) gave an off-rate that was ªtoo slow,º ence in signaling between agonists that can, and antag-
indicating that these kinetic models were not sufficient onists that cannot, produce receptor dimerization in
to describe TCR interactions (Alam et al., 1996). Other BIAcore experiments.
anomalous data have also been found (Al-Ramadi et al., Our data may indicate intermediate steps in the oligo-
1995; Schodin et al., 1996; Sykulev et al., 1998). Alloste- merization of TCR on binding agonist (Reich et al., 1997;
ric models of TCR binding involve the TCR sensing the Monks et al., 1998), since dimerization apparently oc-
structure of the ligand, and responding in a structurally curs after only one of the TCR molecules has bound to
different manner to agonist and antagonist ligands, such ligand. If the initial TCR:MHC-peptide binding induces
dimerization of TCR, then this would induce the bindingas a conformation change of the TCR or a structural
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of another specific MHC-peptide complex (which are that from antagonist-ligated, nondimerized TCRs leads
to positive selection is an important question to be re-normally a tiny minority on an APC surface) to the second
solved.TCR molecule. In terms of the cell biology of T cell
activation, this has the important consequence that it
will drive the accumulation of MHC molecules bearing
Experimental Procedures
the peptide recognized by the TCR in the area of contact
between the T cell and the antigen-presenting cell TCR and MHC Expression
(Monks et al., 1998). Thus, the formation of patches of The OT-1 T cell recognizes the peptide OVA (SIINFEKL) with H-2Kb.
This TCR consists of AV2S7J33 and BV5S2D2J2S6 (Kelly et al.,TCRs would start after the binding of a single molecule
1993). This is the TCR (also known as 149.42 and 42.12) used forto its ligand. The lower limit identified for the density of
analysis of agonist/antagonist and negative/positive selecting ana-ligand capable of activating T cells was one molecule
logs of the OVA peptide (Hogquist et al., 1994, 1995; Jameson et
per cell (Sykulev et al., 1996). Our data may therefore al., 1994; Alam et al., 1996). A second OVA-specific TCR from the
provide an explanation of this finding. cell 149.13 was also used. This TCR differs from OT-1 only at CDR3a
The composition of the TCR-CD3 complex is still un- (OT-1, CAASDNYQLIWG; 149.13, CAVGGNYKPTFG) (Kelly et al.,
1993). The soluble OT-1 TCR was expressed from truncated genescertain, with recent evidence for a stoichiometry of two
in Drosophila S2/M3 cells (Alam et al., 1996; Garcia et al., 1996a,ab TCRs with single ge, de, and zz dimers (Exley et al.,
1996b) or refolded from a bacterial expression system by dialysis1995; JoseÂ et al., 1998). If this is the case, then binding
(Garboczi et al., 1996b), with similar results. The 149.13 sTCR was
of one TCR to ligand could cause the two TCRs within expressed in Pichia as described (Alam et al., 1996; S. Redpath et
the complex to dimerize, perhaps with important effects al., unpublished data). For the Drosophila and Pichia systems, six
histidine residues were added at the C terminus of the a and bon signal transduction. Direct evidence either for con-
chains allowing purification on a Ni-NTA column followed by gel-formational change in TCRs or for dimerization of TCR
filtration on a Superdex HR-200 column. TCR constructs for theis not evident in the available crystal structures of
bacterial expression system were made without a histidine tag.
TCR:MHC-peptide complexes (Garboczi et al., 1996a; Refolded bacterial TCR proteins were purified on DEAE52 anion-
Garcia et al., 1996a; Ding et al., 1998). However, in none exchange resin (Whatman) using 0±500 mM NaCl gradient, followed
of these cases was crystallization carried out at 378C, by gel filtration on Superdex HR-200 and Superdex H75. Kb-peptide
complexes were prepared as described by Zhang and coworkersand at lower temperatures we do not see evidence for
(1992) and correctly refolded MHC-peptide complexes purified ondimerization. Dimerization was, however, suggested
gel-filtration HPLC (Alam et al., 1996).from the structure of a TCR Va domain that formed
dimers of Va homodimers (Fields et al., 1995).
BIAcore SPR AnalysisIn a previous study of temperature dependence of
This was performed as described (Alam et al., 1996). TCR and MHCsTCR binding to class I-peptide complexes on cells,
proteins were passed over a Superdex HR200 gel filtration columnsome complexes bound better at 48C than at 378C, while
just before use to remove aggregates. 500±5000 resonance units
for others, the temperature effect was the opposite [RU] of Kb-peptide complexes were coupled to a CM5 sensor chip
(Schlueter et al., 1996). Dimerization of the TCR might in 10 mM acetate buffer (pH 5.0), using either the standard amine
coupling protocol (Alam et al., 1996) or the maleimide couplingnot have occurred in these experiments, since they were
chemistry described by O'Shanessy et al. (1992). The amine coupledperformed with a soluble single chain Fv form of the
surface was 25%±40% active and the maleimide coupled surfaceTCR, lacking the TCR constant domain and including a
60%±80% active, as detected by conformation-specific MAb. The
linker peptide. The temperature dependence of dimer- sTCR proteins were immobilized using amine coupling at pH 4.5,
ization may explain the lack of clear relationship be- to a level of 2500±4000 RU. This was routinely 30%±40% active as
tween affinity and biological response to certain ligands judged by binding of TCR-specific MAbs. In some experiments,
sTCR was immobilized through binding to amine immobilized anti-(Al-Ramadi et al., 1995; Schodin et al., 1996; Schlueter
Cb MAb H57-597 (Alam et al., 1996). Binding was monitored in aet al., 1996; Sykulev et al., 1998). In studies where soluble
BIAcore 2000 (BIAcore, Inc.) after equilibrating the instrument at the
MHC was measured in binding to cell-surface TCR, the appropriate temperature. After each immobilization and tempera-
rate constants increased with temperature, resulting in ture adjustment, sufficient time was allowed to maintain a stable
lower affinity at 378C than at lower temperatures (Syku- immobilized surface with no base-line drift. In a 258C→378C→258C
temperature cycle, no loss of immobilized ligand was observed.lev et al., 1994b; Luescher et al., 1995). Dimerization or
However, a shift in baseline signal was observed when changingmultimerization of the TCR would not have been noticed
temperatures (z100 RU/18C change). Analyte proteins were preincu-under these experimental conditions.
bated at the same temperature and then injected at a flow rate
The partially activated TCR complexes induced by of 10±50 ml/min. In most cases, agonist and antagonist peptide
recognition of antagonist ligands are not inert and in- complexes were analyzed on the same sensor chip using the same
injection of protein. The buffer was PBS (150 mM NaCl, 0.005%deed suggest a mechanism for antagonist action. The
surfactant P20 [pH 7.4]) maintained at the same temperature as therapid dissociation of the antagonist complexes (com-
instrument using a water bath. This prevented anomalies due to airpared to agonist complexes), and their rebinding to other
bubbles. Rate constant measurements and curve-fitting analyses
TCRs, will engage an excess of TCRs in what can be were performed with the programs SPRevolution (Biotechnology
considered as futile cycles. These partially phosphory- Research Institute, National Research Council, Canada) and BIA-
evaluation 2.1 and 3.0 (BIAcore, Inc.). Rate constant calculationslated receptors may act as a sink for components of the
used only binding curves with minimal effects of mass transportsignaling pathway that will thus be unavailable to fully
limitation, i.e., lower analyte concentrations were often excluded.activated receptors. This is similar to the concepts of
The following kinetic models were used to describe the TCR-MHC
kinetic proofreading (McKeithan, 1995), and particularly, interactions:
kinetic discrimination (Rabinowitz et al., 1996). How sig-
naling from agonist-induced dimerized and multimer- 1. Simple model: single analyte-ligand interaction following the bi-
molecular Langmuir Equation.ized TCRs leads to negative thymic selection whereas
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